On the Market: Interviews on Bedaquiline Use

In April 2015, USAID and Janssen Therapeutics officially launched the bedaquiline (BDQ) donation initiative, under which Janssen committed to providing free BDQ to 30,000 patients with multidrug-resistant tuberculosis (MDR-TB) over a four-year period. Along with delamanid, BDQ is one of only two new TB medicines released to the market in over 40 years. These medicines are being used for the treatment of MDR-TB patients, as well as TB patients who have experienced life-altering side effects or developed intolerance or resistance to some second-line TB drugs.


In the following interviews, SIAPS technical staff discuss the implementation of these new TB medicines:

Ramping Up the Use of New TB Drugs in Uganda: An Interview with Hawa Nakato

New hope for treating drug-resistant TB in Swaziland: An interview with Khontile Kunene

Expanding options for TB patients in Georgia: An interview with Maya Kavtaradze

Leave a Reply

Your email address will not be published. Required fields are marked *